Sunday 18 October 2026 Export ENTA’s income statement to Excel — free account

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024. In the quarter to June 2026, revenue fell 21.6%, EPS grew 21.2% and free cash flow fell 157.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

11.10 0.37 −3.23%

Follow ENTA

Alert me

Market cap: $334.1M
P/E: 0.0×
Fwd P/E: −5.8×
Dividend yield: —
F-score: 4/9
Altman Z: −1.41
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.18

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	9	—	—	—	—	—	—	—	—	—	—

Insider Ownership 4.61%

Capital & Financial Ratios $m

Market Cap 334.07

Revenue 65.26

Net Income (63.23)

Free Cash Flow (36.94)

Net Debt (189.51)

Current Ratio 3.76

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.82)

P/S ratio 4.95

P/B ratio 3.19

Past 5Y EPS Growth —

This Y EPS Growth 40.29%

Next Y EPS Growth 4.13%

Next Y revenue growth (2.03%)

Next 5Y EPS Growth 11.43%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 27.05%

10-year low 10-year high

P/B against its own 10 years 68.60%

10-year low 10-year high

EV/Sales against its own 10 years 7.75%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	370	249	189	190
Receivables	40	39	7	7
Inventory	—	—	—	—
Other	—	—	—	—
	423	300	204	204

	2023	2024	2025	Q'26
Payables	4	8	2	3
ST’ Debt	—	—	—	—
Other	35	34	31	37
	63	58	49	54

Compound Annual Growth %

	10y	5y	3y
Sales	(8.62%)	(11.81%)	(8.82%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(12.14%)	(32.32%)	(41.38%)

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	19	17	14	—	—
’25	17	15	18	15	65
’24	18	17	18	15	68
’23	24	18	19	19	79
’22	28	19	19	20	86
’21	32	20	22	24	97
’20	53	28	19	24	122

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(12)	(7)	(10)	—	—
’25	(17)	(13)	18	(6)	(19)
’24	(25)	(29)	(15)	(10)	(79)
’23	(36)	(14)	(32)	(22)	(103)
’22	(13)	(26)	(30)	(16)	(85)
’21	(15)	(5)	(30)	(21)	(70)
’20	12	15	(4)	(15)	7

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(12)	(7)	(10)	—	—
’25	(26)	(16)	17	(8)	(32)
’24	(26)	(30)	(21)	(19)	(97)
’23	(39)	(16)	(34)	(23)	(112)
’22	(14)	(26)	(30)	(17)	(87)
’21	72	(92)	(30)	(21)	(71)
’20	93	(66)	(5)	(16)	6

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.42)	(0.45)	(0.67)	—	—
’25	(1.05)	(1.06)	(0.85)	(0.87)	(3.84)
’24	(1.58)	(1.47)	(1.07)	(1.36)	(5.48)
’23	(1.39)	(1.79)	(1.86)	(1.33)	(6.38)
’22	(1.48)	(1.63)	(1.53)	(1.27)	(5.91)
’21	(0.41)	(1.09)	(1.19)	(1.22)	(3.92)
’20	0.65	(0.30)	(0.71)	(1.46)	(1.81)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	20.39	25.92	52.39	57.15	38.40	40.37	37.59	8.08	5.30	4.09	Analyst estimates 2026–2028 Powerpack
	High	35.06	59.88	127.77	106.80	62.12	102.00	79.50	62.06	17.80	17.15
People
People	Employees	76	89	113	132	141	155	160	145	131	120
	Revenue/emp, $m	1.16	1.16	1.83	1.55	0.87	0.63	0.54	0.55	0.52	0.54
Income, $m
Income, $m	Revenue	88	103	207	205	122	97	86	79	68	65
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	33	27	93	46	(35)	(108)	(122)	(131)	(118)	(84)
	EBT margin, %	36.89	26.21	45.07	22.20	(28.59)	(110.82)	(141.82)	(165.39)	(174.15)	(127.90)
	Net income	22	18	72	46	(36)	(79)	(122)	(134)	(116)	(82)
	Depreciation	3	3	2	(1)	4	5	4	0	1	5
Per share, $
Per share, $	Revenue	4.66	5.39	10.73	10.48	6.14	4.81	4.18	3.78	3.20	3.06
	Earnings	1.14	0.93	3.74	2.37	(1.81)	(3.92)	(5.91)	(6.38)	(5.48)	(3.84)
	Cash flow	1.89	2.76	1.52	3.65	0.36	(3.47)	(4.11)	(4.92)	(3.72)	(0.90)
	Capex	(0.25)	(0.13)	(0.15)	(0.28)	(0.07)	(0.04)	(0.10)	(0.43)	(0.85)	(0.60)
	Free cash flow	1.64	2.63	1.36	3.37	0.28	(3.51)	(4.22)	(5.35)	(4.57)	(1.51)
	Book value	14.26	15.82	20.45	23.62	22.85	19.80	15.60	10.34	6.09	3.03
	Shares, m	19	19	19	20	20	20	21	21	21	21
Valuation, ×
Valuation, ×	P/E	23.14	51.15	22.61	25.24	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	5.71	8.82	7.84	5.73	7.45	11.80	12.40	2.78	3.24	3.91
	P/B	1.87	3.01	4.11	2.54	2.00	2.87	3.33	1.01	1.70	3.95
	EV/Sales	3.33	6.65	6.34	4.10	4.30	9.29	9.51	(1.89)	(0.44)	1.02
	EV/FCF	9.45	13.63	49.96	12.75	93.25	(12.75)	(9.43)	1.34	0.31	(2.07)
Cash, $m
Cash, $m	Operating cash flow	36	53	29	71	7	(70)	(85)	(103)	(79)	(19)
	Capex	(5)	(3)	(3)	(5)	(1)	(1)	(2)	(9)	(18)	(13)
	Free cash flow	31	50	26	66	6	(71)	(87)	(112)	(97)	(32)
Balance, $m
Balance, $m	Working capital	224	217	364	379	413	283	282	360	242	156
	Total debt	1	1	2	2	10	7	27	222	—	—
	Net debt	(210)	(224)	(309)	(335)	(387)	(244)	(249)	(370)	(249)	(189)
	Shareholders’ equity	270	302	394	462	456	399	321	217	129	65
Returns, %
Returns, %	ROA	8.22	5.83	19.42	10.26	(7.41)	(17.08)	(29.91)	(31.95)	(27.67)	(24.91)
	ROIC	32.21	19.72	64.99	18.04	(37.75)	(44.06)	(107.35)	0.00	0.00	0.00
	ROE	8.56	6.20	20.70	10.83	(7.88)	(18.48)	(33.79)	(49.74)	(67.17)	(84.63)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
FENC Adherex Technologies Inc.	$362.9M	— (loss-making)	31.4×	+85.18% (above 0%: growing)	n/m	+101.36% (above 0%: growing)	95.97%	9.72%	Compare
TTRX Turn Therapeutics Inc.	$345.3M	— (loss-making)	—	—	n/m	−74.76% (below 0%: shrinking)	—	0.00%	Compare
OBIO Orchestra BioMed Holdings, Inc.	$345.0M	— (loss-making)	— (loss-making)	−89.47% (below 0%: shrinking)	n/m	−25.87% (below 0%: shrinking)	71.59%	(25,404.55%)	Compare
CCCC C4 Therapeutics, Inc.	$342.0M	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	+86.84% (above 0%: growing)	100.00%	(397.88%)	Compare
RLMD Relmada Therapeutics, Inc.	$341.3M	— (loss-making)	—	—	n/m	−50.06% (below 0%: shrinking)	0.00%	0.00%	Compare
IRD Opus Genetics, Inc.	$336.9M	— (loss-making)	— (loss-making)	−73.80% (below 0%: shrinking)	n/m	−16.37% (below 0%: shrinking)	100.00%	(2,182.78%)	Compare
ENTA Enanta Pharmaceuticals, Inc.	$334.1M	— (loss-making)	— (loss-making)	−21.60% (below 0%: shrinking)	n/m	−157.51% (below 0%: shrinking)	100.00%	(120.04%)
CYPH Cypherpunk Technologies Inc.	$325.5M	4.4×	— (loss-making)	0.00%	n/m	+15.53% (above 0%: growing)	0.00%	0.00%	Compare
ARCT Arcturus Therapeutics Holdings Inc.	$320.3M	— (loss-making)	— (loss-making)	−89.54% (below 0%: shrinking)	n/m	−245.65% (below 0%: shrinking)	100.00%	(863.30%)	Compare
Median of peers	$341.7M	—	—	−36.90%	—	−21.12%	95.97%	(198.94%)

All 614 Biotechnology stocks →

Enanta Pharmaceuticals, Inc. (ENTA) key facts

Concern: Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024.
Concern: Enanta Pharmaceuticals, Inc. reported a net loss of $81.9 million, or a loss of $3.84 per share, for fiscal 2025.
Enanta Pharmaceuticals, Inc. (ENTA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ENTA traded at $11.10, a market capitalization of $334.1 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.9× sales.
Return on equity was −84.6% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −1.41 (distress zone) for fiscal 2025.